Table 2.
Correlation between the objective response rate and clinicopathological factors in patients with cervical cancer treated with combination immunotherapy.
| Variables | ORR (%) | OR (95% CI) | p |
|---|---|---|---|
| Age (<50 vs. ≥50 years) | 68.75 vs. 55.26 | 0.561 (0.210–1.502) | 0.250 |
| Histology (squamous cell carcinoma vs. adenocarcinoma) | 68.52 vs. 43.75 | 0.389 (0.125–1.214) | 0.104 |
| Disease status (local recurrence vs. distant metastasis) | 59.26 vs. 62.79 | 1.160 (0.433–3.109) | 0.768 |
| Prior radiotherapy (yes vs. no) | 58.93 vs. 71.43 | 1.742 (0.486–6.241) | 0.394 |
| Line of immunotherapy (<3 vs. ≥3) | 69.57 vs. 45.83 | 0.370 (0.134–1.026) | 0.056 |
| NLR (<5.33 vs. ≥5.33) | 78.26 vs. 53.19 | 0.316 (0.100–0.991) | 0.048 |
| PLR (<297.92 vs. ≥297.92) | 70.00 vs. 58.00 | 0.592 (0.195–1.794) | 0.354 |
| MLR (<0.29 vs. ≥0.29) | 80.00 vs. 56.36 | 0.323 (0.082–1.274) | 0.107 |
| SCC-Ag (<2.85 vs. ≥2.85) | 68.57 vs. 54.29 | 0.544 (0.205–1.444) | 0.222 |
| AGR (<1.80 vs. ≥1.80) | 56.90 vs. 83.33 | 3.788 (0.761–18.849) | 0.104 |
| LDH (<195.00 vs. ≥195.00) | 67.31 vs. 44.44 | 0.389 (0.130–1.162) | 0.091 |
| ALP (<87.50 vs. ≥87.50) | 57.14 vs. 65.71 | 1.437 (0.547–3.781) | 0.462 |
Abbreviations: AGR, albumin-to-globulin ratio; ALP, alkaline phosphatase; CI, confidence interval; LDH, lactate dehydrogenase; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; ORR, objective response rate; PLR, platelet-to-lymphocyte ratio; SCC-Ag, squamous cell carcinoma-associated antigen.